Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Sunitinib CANNOT be Co-Administered with the Following Agents1-4

  • Strong CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole, grapefruit)
  • Strong CYP3A4 inducers (e.g. dexamethasone, phenytoin, carbamazepine, rifampicin, rifabutin, rifapentin, phenobarbital, St John's wort)
  • QTc interval-prolonging drugs (e.g. 5HT3 antagonists, antibiotics, antifungals and over-the-counter drugs (e.g. domperidone)

Additional Important Information when Prescribing Sunitinib2,4,5

If co-administration of strong CYP3A4 inhibitors is necessary, consider reducing the sunitinib dose to a minimum of 37.5 mg daily for GIST and mRCC or 25 mg daily for pNET, based on careful monitoring of tolerability.2

If co-administration of CYP3A4 inducers is necessary, consider increasing the sunitinib dose in 12.5 mg increments (up to 87.5 mg per day for GIST and mRCC or 62.5 mg per day for pNET), based on careful monitoring of tolerability.2,3,5

If co-administration of QTc interval-prolonging drugs is necessary, obtain an ECG 24-48 hours before, and 1 week after, the start of concomitant treatment.3

Consider increasing the dose of sunitinib to 75 mg over 24 hours if co-administering with rifampicin.4

Considering decreasing the dose of imatinib to 25 mg over 24 hours if co-administering with ketoconazole.4


  1. Food and Drug Administration. Sunitinib (Sutent) Prescribing information. 2015.
  2. European Medicines Agency. Sunitinib (SUTENT). Summary of Product Characteristics. 2015.
  3. van Leeuwen RW, van Gelder T, Mathijssen RH, Jansman FG. Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol 2014; 15: e315-326.
  4. Pajares B, Torres E, Trigo JM et al. Tyrosine kinase inhibitors and drug interactions: a review with practical recommendations. Clin Transl Oncol 2012; 14: 94-101.
  5. Teo YL, Ho HK, Chan A. Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations. Br J Clin Pharmacol 2015; 79: 241-253.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.